MHRA13 Oct 2026
Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based f
The Medicines and Healthcare products Regulatory Agency published a recall notice for Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes DSI/2026/014 on 13 Oct 2026. It is one of 17 notices of this kind from MHRA since 26 Mar 2026 in AreaZine's record.
Recall
The recall notice
- Issued by
- Medicines and Healthcare products Regulatory Agency
- Issued
- 12:38, 13 Oct 2026
- Alert class
- Medicine Alert
- Official source
- Medicines and Healthcare products Regulatory Agency: the notice at its source
The latest from the MHRAEvery warning and recall in the United Kingdom
Source: Medicines and Healthcare products Regulatory Agency: the notice at its source. AreaZine rebuilds this page from the agency's record; the agency's page is the one to act on. Contains public sector information licensed under the Open Government Licence v3.0.
The notice as issued
Continuous renal replacement therapy (CRRT) is used for managing severe acute kidney injury and fluid overload. Published evidence has shown that caspofungin can bind to polyacrylonitrile (PAN)-based membranes used in CRRT w…
Source: Medicines and Healthcare products Regulatory Agency: the notice at its source. The text is the agency's, unedited. Contains public sector information licensed under the Open Government Licence v3.0.